CHARLES RIVER LABORATORIES INTERNATIONAL, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 215.8 EUR | -2.40% |
|
-.--% | -.--% |
| 06-13 | Baird Adjusts Price Target on Charles River Laboratories International to $271 From $270 | MT |
| 06-07 | The job report just threw a spanner in the works |  |
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- With a 2024 P/E ratio at 26.34 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -.--% | 10.79B | - | ||
| +40.80% | 53.67B | B- | ||
| +35.79% | 38.86B | A | ||
| -8.05% | 38.76B | B | ||
| -8.98% | 27.27B | C | ||
| +10.69% | 25.91B | B- | ||
| -16.21% | 20.29B | B | ||
| +31.00% | 12.78B | B+ | ||
| +28.51% | 12.18B | C+ | ||
| -1.67% | 11.96B | B+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- CRL Stock
- RV6 Stock
- Ratings Charles River Laboratories International, Inc.